Status:
COMPLETED
Abciximab i.v. Versus i.c. in Primary PCI Patients With STEMI
Lead Sponsor:
University of Leipzig
Conditions:
Myocardial Infarction
Eligibility:
All Genders
18+ years
Phase:
PHASE2
PHASE3
Brief Summary
Randomized comparison of abciximab i.v. versus i.c. in patients with STEMI undergoing primary PCI. The hypothesis is, that higher concentration of abciximab i.c. leads to improved epicardial flow, per...
Eligibility Criteria
Inclusion
- Clinical symptoms:
- Angina \< 12 h persistent Angina \> 30 min.
- ECG-Criteria:
- ST-elevation \> 1mm in ≥ 2 extremity leads
- ST-elevation \> 2mm in ≥ 2 contiguous anterior leads
- Informed consent
Exclusion
- No consent
- Pregnancy
- Allergy against abciximab, ASA or heparin
- Active peptic ulcus ventriculi or duodeni
- Active non-superficial bleeding
- Major surgical intervention, intracerebral interventions, puncture central artery \< 4 weeks
- Active internal bleeding
- Cerebrovascular complications \< 2 years
- Known coagulation disorders, thrombocytopenia
- Arteriovenous malformations or aneurysms
- Severe Liver or renal dysfunction
- Severe untreated hypertension
- Active vasculitis
- Previous thrombolysis \< 12 h
Key Trial Info
Start Date :
January 1 2006
Trial Type :
INTERVENTIONAL
End Date :
February 1 2008
Estimated Enrollment :
150 Patients enrolled
Trial Details
Trial ID
NCT00299377
Start Date
January 1 2006
End Date
February 1 2008
Last Update
July 3 2008
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
University of Leipzig - Heart Center
Leipzig, Germany, 04289